CJC-1295 No DAC and Ipamorelin: Research Focus Considerations

CJC-1295 no DAC and ipamorelin are two distinct research compounds that sit in the same broad area of growth-hormone-axis investigation but act through different receptor systems. CJC-1295 without DAC is a modified analog of growth-hormone-releasing hormone (GHRH), studied at the GHRH receptor. Ipamorelin is a short synthetic pentapeptide described in the research literature as a selective growth hormone secretagogue acting at the ghrelin receptor (GHS-R). For a wholesale buyer, the considerations that actually matter are analytical and operational: per-batch identity, per-batch purity, documentation you can read before you commit to volume, and a supplier whose labeling distinguishes the no-DAC molecule from its longer-acting counterpart. Both are research-use-only materials, and nothing below describes human use.

Two receptor pathways that get filed under one heading

The reason these two compounds appear adjacent in almost every research catalog is that published work on the growth-hormone axis has historically approached it from two directions. GHRH analogs are investigated at the GHRH receptor on somatotroph cells. Secretagogues of the ipamorelin type are investigated at the ghrelin receptor, a separate receptor with its own signaling cascade. Preclinical literature suggests the two pathways are complementary rather than redundant, which is why study designs frequently include compounds from both classes when the research question concerns pathway interaction rather than a single receptor.

That is compound science, and it is where the description should stop. Research on either molecule does not translate into a claim about what a compound does for a person, and a wholesale supplier that pitches it that way is telling you something about its compliance posture. Published preclinical work also describes ipamorelin as comparatively selective within its class — studies report a more targeted receptor profile than earlier secretagogues — but selectivity in an animal or in-vitro model is a finding about the molecule, not a promise, and honest catalogs present it that way.

For your purposes as a buyer, the useful takeaway is that these are two separate SKUs with two separate analytical fingerprints. They are not grades of the same thing, and a certificate of analysis for one tells you nothing about the other.

Why the 'no DAC' in the name changes the molecule

DAC stands for Drug Affinity Complex — a moiety attached to the peptide that allows it to bind covalently to serum albumin, which substantially extends how long the molecule persists in circulation. CJC-1295 with DAC carries that attachment. CJC-1295 no DAC does not. Without it, the compound is essentially a tetrasubstituted GHRH(1-29) fragment, the material often catalogued as modified GRF 1-29, and its circulating half-life is short by comparison.

This is the single most common source of confusion in this corner of the market, and it has direct commercial consequences. The two variants have different molecular weights, different synthesis costs, and different price positions. A listing that says only 'CJC-1295' without specifying the variant is either careless or deliberately ambiguous, and both are problems when you are the one reselling it. Ambiguity at the listing level usually means ambiguity at the documentation level.

So the first verification step is not purity. It is identity. A mass-spectrometry result on the batch COA should correspond to the no-DAC molecular weight, and the batch number on that COA should match the vial label on what arrives. If a supplier cannot produce that correspondence on demand, the purity figure underneath it is not worth much, because you do not yet know what was tested.

Side-by-side on the attributes a buyer evaluates

What to verify before either compound enters your catalog

The verification list is the same for both, and it is short enough that there is no excuse for skipping it.

Batch-specific documentation, not a specimen COA. A COA for a batch you will never receive is marketing. The document should carry the batch identifier for the lot you are buying, and you should be able to pull it up yourself rather than requesting it through a sales rep. Suppliers that treat lab results as a gated asset — available on request, available after purchase, or available for a fee — have made a choice about transparency that you should factor into your decision.

Purity by HPLC, with the method visible. A purity percentage without a chromatogram or a stated method is a number on a page. Ask what the figure represents and how it was produced.

Peptide content as a separate line item. HPLC purity describes the proportion of peptide material that is the target sequence. Peptide content describes how much of the vial's mass is peptide at all, as opposed to residual salts and water from lyophilization. They are different measurements, and a COA that reports only one gives you an incomplete picture.

Contamination panels. Beyond identity and purity, the questions worth asking concern residual solvents, heavy metals, sterility, and endotoxin. You do not need to become an analytical chemist; you need to be able to read which panels ran on your lot and which did not.

Fulfillment and consistency. Lot-to-lot consistency is what lets you build a catalog customers return to. Ask how a supplier handles a batch that fails internal specification, how long orders take to ship domestically, and whether the answer changes when your volume doubles.

Questions to put to your own counsel before reselling

This section is informational and is not legal advice. Whether your business can hold, resell, or distribute research-use-only compounds depends on your entity type, your state, your professional licensure if any, and how you market — and none of those questions can be answered from a blog post.

The productive move is to arrive at your attorney's office with the right questions rather than looking for a rule online. Ask how research-use-only materials are treated for a business structured like yours, and what that classification does and does not permit. Ask what your state board, if you hold a professional license, expects regarding materials that are not approved drugs. Ask what labeling, record-keeping, and customer-representation obligations attach to reselling. Ask specifically where the line sits between describing research and making a health claim in your marketing copy, because that line is where most compliance exposure in this industry actually lives. Regulatory interpretation in this space is unsettled and varies by jurisdiction, so treat any supplier that hands you a confident legal conclusion as a red flag rather than a resource.

On the operational side, separate two things in your own mind: your supplier's compliance and your own. A supplier can document what it sells and how it tested it. Only your counsel can tell you what your business may do with it.

How wholesale pricing tiers and order minimums generally work

Wholesale programs in this category are usually tiered by volume, with unit pricing improving as committed quantity rises, and minimums set per SKU or per order depending on the supplier. Beyond that structural generalization, be skeptical of anyone quoting you industry-standard margins or typical minimums as though they were published figures — they vary widely by compound, synthesis complexity, and the size of the relationship, and a specific number offered without a source is usually invented.

What you can evaluate concretely is whether pricing is visible before you apply, whether tier thresholds are stated plainly, and whether the price you were quoted is the price you pay once testing documentation and shipping are accounted for. Programs that require a call before revealing any pricing are optimizing for negotiation leverage, not for your planning. Programs that charge separately for lab documentation are charging you to verify the thing you already bought.

What Real Peptides does differently

Real Peptides operates its Wholesale Partner Program on a small set of stated commitments rather than promises about your results.

Compounds are supplied at 99%+ HPLC purity. Every batch goes through 7-panel testing, and the resulting certificates of analysis are publicly verifiable — meaning a prospective partner can read the lab results for a lot before applying, without asking a sales representative for permission and without paying for the document. That last point is the practical difference between a supplier whose testing is a claim and one whose testing is a record you can check. Fulfillment is handled domestically in the United States, with orders shipping in 5–7 days.

Applying is a 3-step process: submit the wholesale application, complete verification of your business, and receive tier pricing. Catalog listings distinguish variants explicitly, which for this topic means the no-DAC molecule is listed and documented as the no-DAC molecule rather than folded into a generic name.

Real Peptides does not provide dosing, reconstitution, or preparation guidance for any compound, and will not — these are research-use-only materials, and that framing holds in the catalog, in the documentation, and in conversations with partners.

If your business is positioned to stock GHRH-pathway and secretagogue research compounds and you want documentation you can hand to your own compliance reviewer, the Wholesale Partner Program application is where that conversation starts; qualified applicants move through business verification and receive tier pricing without a gated sales call first.

Partners evaluating this category typically review CJC-1295 No DAC 10mg and Ipamorelin 10mg alongside related GHRH-pathway material such as Tesamorelin 10mg, and the broader Growth Factor & Tissue Signaling Research and Performance & Recovery Research collections show how the catalog is organized by research pathway rather than by marketing category.